

Figure S1. Dose-responsive curve of 5-FU in SQUU-B using RTCA system. Dose-responsive curve at 24, 48, 72 h after addition of 5-FU were described. 5-FU, 5-fluorouracil; RTCA, real-time cell analysis.




Figure S2. Dose-responsive curve of doxifluridine in SQUU-B using RTCA system. Dose-responsive curve at 24, 48, 72 h after addition of doxifluridine were described. RTCA, real-time cell analysis.




Figure S3. Dose-responsive curve of carboplatin in SQUU-B using RTCA system. Dose-responsive curve at 24, 48, 72 h after addition of carboplatin were described. RTCA, real-time cell analysis.




Figure S4. Dose-responsive curve of docetaxel in SQUU-B using RTCA system. Dose-responsive curve at 24, 48, 72 h after addition of docetaxel were described. RTCA, real-time cell analysis.




Figure S5. Cell viability curve of 5-FU in SQUU-B using WST-8 assay. Cell viability curve at 24, 48, 72 h after addition of 5-FU were described. 5-FU, 5-fluorouracil; RTCA, real-time cell analysis.




Figure S6. Cell viability curve of doxifluridine in SQUU-B using WST-8 assay. Cell viability curve at 24, 48, 72 h after addition of doxifluridine were described.




Figure S7. Cell viability curve of carboplatin in SQUU-B using WST-8 assay. Cell viability curve at 24, 48, 72 h after addition of carboplatin were described.




Figure S8. Cell viability curve of docetaxel in SQUU-B using WST-8 assay. Cell viability curve at 24, 48, 72 h after addition of docetaxel were described.

